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Since the emergence of the Severe Acute Respiratory Syndrome Coronavirus-2
(SARS-CoV-2) in December 2019, the scientific community has been sharing data
on epidemiology, diagnostic methods, and whole-genomic sequences almost in real
time. The latter have already facilitated phylogenetic analyses, transmission chain
tracking, protein modeling, the identification of possible therapeutic targets, timely risk
assessment, and identification of novel variants. We have established and evaluated an
amplification-based approach for whole-genome sequencing of SARS-CoV-2. It can be
used on the miniature-sized and field-deployable sequencing device Oxford Nanopore
MinION, with sequencing library preparation time of 10 min. We show that the generation
of 50,000 total reads per sample is sufficient for a near complete coverage (>90%) of
the SARS-CoV-2 genome directly from patient samples even if virus concentration is
low (Ct 35, corresponding to approximately 5 genome copies per reaction). For patient
samples with high viral load (Ct 18–24), generation of 50,000 reads in 1–2 h was
shown to be sufficient for a genome coverage of >90%. Comparison to Illumina data
reveals an accuracy that suffices to identify virus mutants. AmpliCoV can be applied
whenever sequence information on SARS-CoV-2 is required rapidly, for instance for the
identification of circulating virus mutants.
Keywords: SARS-CoV-2, MinION, whole-genome sequencing, ampliseq, mutation detection
INTRODUCTION
In November 2002, an outbreak of atypical pneumonia was reported in Guangdong, Southern
China (Zhao et al., 2003; Zhong et al., 2003). On 16 April 2003, the continuing outbreak was
announced by the World Health Organization to be caused by a novel coronavirus (CoV), termed
Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV; World Health Organization
[WHO], 2003b). The first whole-genome sequences of the novel virus were made available on
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30 May 2003, more than 6 months after the first reported cases
(Marra et al., 2003; Rota et al., 2003). Until then, the viral
disease had caused more than 8,000 infections and over 750
deaths (World Health Organization [WHO], 2003a) and not
much was known about the virus’ phylogeny, origin, and routes
of transmission.
Seventeen years after the emergence of the first human-
pathogenic CoV of the 21st century, the world is being challenged
by a novel CoV similar to SARS-CoV, termed SARS-CoV-2. Cases
of patients with unknown pneumonia in Wuhan, China, were
officially reported on 31 December 2019 (The Government of the
Hong Kong Special Administrative Region, 2019). Only 1 week
later, on 8 January 2020, the novel CoV was identified from
patient samples, followed by the release of the first whole-genome
sequence of the virus on the following day (Holmes, 2020; Khan,
2020; World Health Organization [WHO], 2020). As of 17 March
2021, 119,960,700 diagnosed cases worldwide with 2,656,822
deaths from SARS-CoV-2 infections have been reported1.
The rapid discovery of SARS-CoV-2 and the prompt
publication of whole-genome sequences demonstrate that thanks
to modern technologies the response to disease outbreaks has
improved markedly since the SARS-CoV outbreak. To date,
more than 792,347 SARS-CoV-2 genome sequences have been
published on GISAID (Global Initiative on Sharing all Influenza
Data; GISAID, 2020). The genomic data have enabled extensive
analyses of phylogenetics and transmission chains, including
the report of a proposed single introduction into the human
population, probably having occurred in Wuhan in November or
early December 2019 (Andersen et al., 2020).
The rapid publication and analysis of full genome sequences of
SARS-CoV-2 have been achieved with the development of High-
Throughput Sequencing (HTS). The most common platforms for
HTS are the Illumina sequencing devices. Generated sequences
from clinical samples are accurate and of high quality, but
costs for acquisition of the device and reagents as well as for
data storage are high. In addition, sequence information for
the host is usually generated by shotgun approaches, conflicting
with personal data protection. The Oxford Nanopore MinION
(Oxford Nanopore Technologies, Oxford, United Kingdom) is a
portable long-read sequencing device that offers sequencing in
real time. The low acquisition and reagent costs have enabled
sequencing for numerous smaller laboratories and even under
field conditions. However, compared with Illumina sequencing,
the quality of the sequences is low and can challenge the
identification of Single Nucleotide Polymorphisms, insertions,
and deletions in sequenced genomes. Such difficulties can be
overcome by a high read coverage of the genome, which can
be achieved by amplicon sequencing as has been performed
during the Ebola virus epidemic in 2014, for Zika virus, and
more recently for SARS-CoV-22 (Quick et al., 2016, 2017;
Freed et al., 2020; Gohl et al., 2020; Hourdel et al., 2020).
Moreover, specific amplification of the viral genome excludes




In this study, we evaluate a two-reaction multiplex PCR
with 113 and 111 primers, which can be used for amplification
and whole-genome sequencing of SARS-CoV-2 in less than 3 h
from sample to result on the Oxford Nanopore MinION. The
method can also be performed with a rapid library preparation
time of only 10 min. After establishment of AmpliCoV using
SARS-CoV-2 propagated in cell culture and samples obtained
through the INSTAND external quality assurance exercise for
molecular diagnostics of SARS-CoV-2, we analyzed various
clinical specimens to prove the applicability of AmpliCoV in
routine diagnostics, to elucidate transmission chains, and to
identify virus mutants that may contribute to more efficient
transmissibility.
MATERIALS AND METHODS
Primer Design and Evaluation
Primers have been designed by using Primer3 v2.3.7 (Untergasser
et al., 2012). For the primer design, all references for SARS-
CoV-2 available on GISAID (23 January 2020) and the NCBI
RefSeq reference for SARS-CoV-1 (NC_004718) were aligned
by using MAFFT v7.450. If possible, primers were designed
on regions conserved between all SARS-CoV-2 and SARS-CoV
sequences to enable amplification also at regions with possibly
arising mutations. We designed the primers to cover the whole
genome with tiled primers separated into two pools (113 and 111
primers), with amplicon sizes between 199 and 775 bp (average
415 bp), with overlaps between the amplicons between 7 and
258 bp (Supplementary Material and Table 2), excluding the 3′
and 5′ ends of the genome (bases 0–68 and 29,830–29,904). All
primers have been selected based on their melting temperature
Tm (minimum Tm 59◦C, maximum Tm 61◦C, and optimal
Tm 60◦C) and resulting amplicon length (250–650 bp). Primer
sequences are shown in Supplementary Table 1.
Evaluation of AmpliCoV Sequencing With
Cell Culture-Propagated Virus Strains
and Human Clinical Specimens
The performance of the AmpliCoV sequencing of SARS-
CoV-2 was evaluated with selected virus strains. Nucleic acids
from cultured SARS-CoV-2 strain hCoV-19/Italy/INMI1-
isl/2020 (National Institute for Infectious Diseases, Rome,
Italy, GISAID Accession EPI_ISL_410545), SARS-CoV-2
strain hCoV-19/Germany/BY-ChVir-929/2020 (Institut für
Mikrobiologie der Bundeswehr, Munich, Germany, GISAID
Accession EPI_ISL_406862), and strain hCoV-19/Japan/TY-
WK-521/2020 (Laboratory of Neurovirology, National Institute
of Infectious Diseases, Toyama, Tokyo, Japan, GISAID Accession
EPI_ISL_408667) were extracted with the QIAamp Viral
RNA Mini Kit (Qiagen, Hilden, Germany). cDNA synthesis was
performed according to the SuperScript IV Reverse Transcriptase
protocol (Thermo Fisher Scientific, Waltham, MA, United States)
with random hexamers (65◦C for 5 min and 23◦C for 10 min),
followed by incubation at 55◦C for 10 min and inactivation at
80◦C for 10 min. Relative genome concentration of all strains
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TABLE 1 | AmpliCoV sequencing of SARS-CoV-2-positive clinical specimens from Germany, direct comparison of rapid library and ligation library.









Rapid library* Ligation library*
AC_01 18.1 98.4 02:42:41 97.3 00:53:15
AC_02 18.4 97.3 01:45:58 96.4 00:40:15
AC_03 24.7 94.4 02:42:35 91.9 00:31:16
AC_04 23.3 96.0 02:41:20 93.6 00:44:32
AC_05 17.7 96.9 01:44:46 95.9 00:40:09
AC_06 21.9 96.0 01:57:23 94.1 00:42:05
AC_07 23.2 95.0 02:33:40 95.0 00:35:09
AC_08 22.1 92.0 01:39:19 92.6 00:40:29
*Multiplexing of 11 samples on one flow cell.
was determined by specific quantitative real-time PCR (Michel
et al., 2021). The performance of the AmpliCoV sequencing
was further tested on clinical specimens (n = 36) from patients
with a clinical and laboratory diagnosis of COVID-19. All
specimens are listed in Tables 1–3. Three additional specimens
were analyzed to prove transmission chains and to identify virus
mutants, respectively. Ethics approval was obtained from the
Berliner Ärztekammer (#Eth 20/40).
Evaluation of AmpliCoV Sequencing via
Samples of an INSTAND Quality
Assurance Exercise
The AmpliCoV method was further tested with samples for
a national quality assurance exercise provided by INSTAND
e.V. INSTAND e.V. offers exercises for quality assurance for
medical laboratories across Germany. This exercise focused on
the genomic detection of SARS-CoV-2 and contained inactivated
TABLE 2 | AmpliCoV Sequencing of SARS-CoV-2-positive clinical specimens from
Germany, rapid library.
Sample ID Ct Percentage genome coverage with
depth coverage > 10 after








No of samples on
flow cell
ACR_01 18.6 98.4 02:24:53 6
ACR_02 19.1 98.6 01:51:49 6
ACR_03 20.1 99.2 02:27:03 11
ACR_04 20.5 98.1 01:39:19 11
ACR_05 20.5 99.2 02:20:57 11
ACR_06 21.4 98.8 02:01:01 6
ACR_07 23.1 98.3 02:47:14 11
ACR_08 26.2 96.7 01:55:32 6
ACR_09 30.0 93.4 02:36:49 11
ACR_10 31.0 96.9 13:56:26 11
samples for sensitivity (SARS-CoV-2 in different concentrations)
and specificity assessment (e.g., other coronaviruses).
PCR Amplification
The samples were amplified in two reactions with primer pool A
and primer pool B designed for whole-genome amplification of
SARS-CoV-2 with the following PCR conditions for each primer
pool: 3 µl of viral cDNA,1.6 µl of primer pool (100 µM), 0.2 mM
dNTP (Invitrogen, Karlsruhe, Germany), 4 µl of 10 × Platinum
TABLE 3 | AmpliCoV Sequencing of SARS-CoV-2-positive clinical specimens from
Germany, ligation library.
Sample ID Ct Percentage genome coverage with
depth coverage > 10 after








No of samples on
flow cell
ACL_01 18.5 99.1 01:13:18 11
ACL_02 19.6 99.2 01:21:10 11
ACL_03 19.9 99.3 01:34:57 11
ACL_04 20.5 99.2 01:07:23 11
ACL_05 22.1 99.1 01:11:25 11
ACl_06 22.0 99.1 01:08:16 11
ACl_07 25.3 99.2 01:35:11 15
ACl_08 26.1 99.1 01:44:12 15
ACl_09 26.9 99.0 01:08:26 15
ACl_10 28.1 98.6 00:09:34 5
ACl_11 29.6 97.4 01:58:46 20
ACl_12 29.7 97.3 03:29:22 11
ACl_13 30.1 95.3 05:55:00 20
ACl_14 31.0 97.4 00:56:08 8
ACl_15 31.0 96.6 00:42:21 8
ACl_16 32.0 96.6 01:27:33 8
ACl_17 34.5 89.9 11:50:54 11
ACl_18 35.0 92.2 16:08:41 8
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Taq buffer, 2 mM MgCl2, and 5 U Platinum Taq polymerase
(Invitrogen) with added water to a final volume of 25 µl. Cycling
conditions were 94◦C for 5 min, 45 amplification cycles at 94◦C
for 20 s, 65◦C for 30 s, 72◦C for 30 s, and a final extension
step for 5 min (at 72◦C). Thermal cycling was performed in an
Eppendorf Mastercycler Pro (Eppendorf Vertrieb Deutschland,
Wesseling-Berzdorf, Germany) with a total runtime of 84 min.
Library Preparation and NGS Sequencing
For MinION sequencing, amplicons were processed for nanopore
sequencing via MinION (Oxford Nanopore Technologies). The
libraries were prepared by using the Rapid Barcoding Kit, SQK-
RBK004 (Oxford Nanopore Technologies), and the Ligation
Sequencing Kit, LSK-109. Before library preparation, the PCR
reactions were purified with AMPure XP Beads in a ratio of 1:1
(Beckman Coulter Diagnostics, Brea, CA, United States). The
barcoded samples were then combined and concentrated with
AMPure XP Beads in a ratio of 1:1. Subsequently, the libraries
were loaded onto Oxford Nanopore MinION SpotON Flow
Cells FLO-MIN106D, R9.4.1 (Oxford Nanopore Technologies).
The cell culture-propagated virus strains were prepared with
the Rapid Barcoding Kit and sequenced on single SpotON
Cells each; the patient samples were prepared with the Rapid
Barcoding Kit and Ligation Sequencing Kit, barcoded, combined,
and sequenced on one SpotON Cell; the samples of the INSTAND
quality assessment study were prepared with the Ligation
Sequencing Kit, barcoded, and sequenced on a SpotON Flow Cell.
Since patient samples were sequenced as part of the routine virus
diagnostics, different levels of multiplexing barcodes were applied
based on the number of samples, and Flow Cells with variable
active pore numbers were used.
For Illumina sequencing, cDNA and double strand
cDNA synthesis was performed using Superscript IV reverse
transcriptase (Thermo Fisher Scientific, Darmstadt, Germany)
and Non-directional RNA Second Strand Synthesis Module (New
England Biolabs, Ipswich, MA, United States). Sequencing was
performed on the Illumina MiSeq with the Paragon CleanPlex
assay (Paragon Genomics, Hayward, CA, United States).
Bioinformatics Analysis
The Fast5 files generated during sequencing were basecalled
to FastQ files by using Guppy v.3.4.5 (Oxford Nanopore
Technologies) on the MinION IT device (MNT-001).
Furthermore, barcoded reads were demultiplexed and identified
barcodes were clipped. The reads separated by barcode were then
further trimmed with Porechop3, removing residual barcode and
adapter sequences and separating chimeric reads into separate
reads. The trimmed FastQ reads for each sample were aligned
to the used strain reference if known; for patient samples strain
Wuhan-Hu-1 (Accession NC_045512) was used as a reference
with Guppy v.3.4.5. Based on the resulting BAM files, primer
sequences were soft clipped with bamclipper v.1.1.1 and all soft
clippings from the BAM file were removed with custom python
scripts. The assembled file was then polished and the consensus
3https://github.com/rrwick/Porechop
sequence was called using medaka v. 1.2.34. Furthermore, the
resulting consensus sequences were masked at regions with
coverage depth <10, based on bedtools v2.26.0 genomecov
histograms5 with custom python scripts. Ambiguities and indels
in homopolymer regions were corrected manually, based on the
reference genome. For each sample, 50,000 reads were analyzed.
All sequence data is deposited under the project number
PRJEB42647 at the European Nucleotide Archive.
RESULTS
Whole-Genome Sequencing of Cell
Culture-Propagated SARS-CoV-2
Sequencing of the amplified DNA from the isolates
hCoV-19/Germany/BY-ChVir-929/2020, hCoV-19/Italy/INMI1-
isl/2020, and hCoV-19/Japan/TY-WK-521/2020 was performed
on Oxford Nanopore SpotON (478–654 active pores) Flow Cells.
Whole-genome sequencing of SARS-CoV-2 could be performed
for all three isolates with >98% genome coverage after generation
of 75,000 reads, with a coverage depth >10 for all regions on a
SpotON Flow Cell (01:24-01:56 h of sequencing time, Figure 1).
Although MinION-generated sequences are prone to high error
rates, the identified genome sequences were 100% identical to
the reference genomes, except for strain hCoV-19/Italy/INMI1-
isl/2020, which had one SNP at genome position 2269, which was
confirmed after repeated sequencing. The high accuracy could be
shown for sample preparation with the Ligation Kit as well as the
Rapid Kit where crossover of barcodes can be observed because
of less stringent demultiplexing with only a single barcode being
present on the read.
To analyze the performance of AmpliCoV sequencing with
potentially cross-reacting coronaviruses, SARS-CoV, HKU1,
NL63, OC43, and 229E were amplified with the AmpliCoV
primers. No amplification was shown for HKU1, NL63, OC43,
and 229E. Although for SARS-CoV the amplification failed for
some genome regions with no matching primers, those genomic
regions with up to two mismatches between primers and genome
sequence were still amplified with low coverage, demonstrating
that AmpliCoV could even be performed with increasing
genome mutation of SARS-CoV-2. However, after sequencing,
all amplicons of SARS-CoV could be distinguished from SARS-
CoV-2, eliminating wrong identification and false positives.
Evaluation on INSTAND External Quality
Assurance Exercise Samples
The AmpliCoV method was further tested with samples provided
by INSTAND e.V. for quality assurance for SARS-CoV-2
diagnostics in medical laboratories across Germany. All seven
samples and a negative control were barcoded and prepared with
the LSK-109 Ligation Kit for library preparation and sequenced
on a SpotON Flow Cell. The results were identical for all samples
tested with specific SARS-CoV-2 qPCRs and AmpliCoV. Genome
coverage between 94% (Ct 28.2) and 99.6% (Ct 21.4) could be
4https://github.com/nanoporetech/medaka
5https://bedtools.readthedocs.io/en/latest/
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FIGURE 1 | Coverage (depth) for the genome of SARS-CoV-2 strain hCoV-19/Italy/INMI1-isl/2020, hCoV-19/Germany/BY-ChVir929/2020 and
hCoV-19/Japan/TY-WK-521/2020 after generation of 10,000–100,000 reads with the AmpliCoV approach. Ct values reflect the amount of 3 µl of cDNA, transcribed
from 1.5 µl of viral RNA.
achieved for samples positive for SARS-CoV-2 (Ct 21.4–31.3;
Table 4). No reads for OC43 or 229E were identified.
Whole-Genome Sequencing of
SARS-CoV-2 From Human Clinical
Specimens of Varying Virus Load
For further validation of AmpliCoV sequencing, samples from
patients diagnosed with SARS-CoV-2 by PCR were amplified,
prepared with the Rapid Barcoding and Ligation Sequencing
Kit, and sequenced on Oxford Nanopore SpotON Flow Cells
until generation of 50,000 reads per sample (Tables 1–3). The
consensus sequences and percentage genome coverages were
calculated for regions with depth coverage > 10. For low Ct values
(Ct 17–23), sequencing with both Rapid and Ligation Sequencing
Kit could generate genomes with genome percentage coverages
of 92.6–99.3% (Ligation Sequencing, Tables 1, 3) and 92.0–99.2%
(Rapid Sequencing, Tables 1, 3). With a Ct range of 24–29,
genome percentage coverages from 91.9–99.2% were achieved
(Ligation Sequencing, Tables 1, 3). With the Rapid Sequencing
Kit, no samples with Ct > 31 could be sequenced, whereas
sequencing of samples with Ct of up to 35.0 was possible with
the Sequencing by Ligation Kit (genome percentage coverage
of 92.2%, Table 3). However, sequencing times increased from
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TABLE 4 | Results of AmpliCoV and specific qPCRs of the INSTAND exercise for
quality assurance for SARS-CoV-2 diagnostics.




INSTAND-340059 SARS-CoV-2 21.4 SARS-CoV-2 99.6%
INSTAND-340060 OC43 25.3 Negative
INSTAND-340061 SARS-CoV-2 31.3 SARS-CoV-2 95.3%
INSTAND-340062 Negative Negative
INSTAND-340063 SARS-CoV-2 24.6 SARS-CoV-2 99.1%
INSTAND-340064 SARS-CoV-2 28.2 SARS-CoV-2 94.0%
INSTAND-340065 229E 24.7 Negative
NK Negative Negative
01:13 h (Ct 18.5) and 01:27 (Ct 32.0) up to 11:50 h (Ct 34.5)
and 16:08 h (Ct 35.0). In direct comparison of both methods for
library preparation, sequencing times were longer for the Rapid
Library Kit, whereas genome percentage coverage was slightly,
but not significantly higher (Table 1). The genomes generated by
the Rapid and Ligation Sequencing Kit were identical in direct
comparison, except for single indels in homopolymer regions,
which were corrected manually.
Following discussions about SARS-CoV-2 mutants circulating
in minks in Denmark and elsewhere that may represent escape
mutants with respect to the newly developed vaccines, we could
show by in silico analysis that AmpliCoV could rapidly and
reliably show respective mutations in short time (data not
shown). Similarly, the recently described SARS-CoV-2 mutants
from the United Kingdom (for example the B.1.1.7. variant),
displaying a more efficient transmissibility, can be identified by
AmpliCoV. Figure 2 comprises the S gene sequence of SARS-
CoV-2 in relation to the primer sequences used with AmpliCov
for the S gene region. AmpliCoV sequencing of three patient
specimens (Ct values Seq-001 = 21.4, Seq-002 = 20.9, and Seq-
003 = 32.3) suspected to be B.1.1.7. variants resulted in almost
complete coverage of the S gene sequence (genome percentage
coverage with coverage depth > 10 of 100, 96.2, and 85.2%)
with identification of all possible sites of mutation except for
mutation D1118H for sequence Seq-003. For Seq-003, taken
from a patient after returning from London, United Kingdom,
AmpliCoV sequencing enabled identification of 8 out of 9
mutations described for B.1.1.7. in the S gene. For sequences Seq-
001 and Seq-002, sampled from a severe hospital outbreak, only
mutation D614G could be identified.
Application of AmpliCoV to Elucidate
Virus Transmissions
After diagnosing a SARS-CoV-2-positive patient in a co-working
space, a PCR screening revealed two additional PCR-positive
cases (Ct values specimen 1 = 18.8, specimen 2 = 27.0, and
specimen 3 = 19.2). AmpliCoV was used to generate the genome
sequences in 1:30 h in total with percentage genome length
coverages of 98.2, 97.5, and 98.2% (mean depth of coverage
of 3614, 3681, and 7378). Genome analysis showed that there
was no relationship between the three cases, pointing toward
independent infection events. Illumina sequencing confirmed
the AmpliCoV results with the method-inherent delay. In
direct comparison of the genomes generated by Illumina
sequencing and MinION AmpliCoV sequencing, no SNPs could
be identified, except for single indels in homopolymer regions,
which were corrected within the bioinformatics generation of the
consensus sequences.
DISCUSSION
Whole-genome sequencing of SARS-CoV-2 has been an
integral part of outbreak investigations since the identification
of the first COVID-19 cases. As of 17 March 2021, more
FIGURE 2 | Schematic illustration of the SARS-CoV-3 spike protein with all main mutations of the spike protein (deletions 69–70, deletion 144, N501Y, A570D,
D614G, P681H, T716I, S982A, and D1118H) in reference to hCoV-19/England/CAMC-C44C79/2020| EPI_ISL_718552| 2020-12-10. Seq-001 to Seq-003
represent clinical specimens carrying different mutations in the S gene.
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than 792,347 genomes of SARS-CoV-2 have been made
available on GISAID, and additional genomes are being
added daily. Recently, the WHO has outlined current and
future benefits of real-time virus genome data sharing during
outbreaks (World Health Organization [WHO], 2017). Genomic
surveillance can be relevant for several outbreak investigations,
including virus diversity, virulence, transmission routes,
possible mutations, identification of hotspots of transmission,
improvement of molecular diagnostics tools and therapeutics.
The relevance of whole-genome sequencing has been shown
during several viral outbreaks (Grubaugh et al., 2019). For
example, the sequencing and analysis of more than 1,600
Ebola virus genomes during the epidemic in West Africa
in 2013–2016 has shown mutations in the virus genome
compatible with increased fitness because of host adaption
(Diehl et al., 2016; Urbanowicz et al., 2016). During the Zika
outbreak in 2016, sequencing and phylogenetic analyses of
Zika virus from patients and mosquitoes could show multiple
introduction events (Grubaugh et al., 2017). Also in the current
outbreak of SARS-CoV-2, the comprehensive collection of
whole-genome sequences that is updated daily has enabled
the calculation and analysis of phylogenetic trees, receptor
binding surveillance, important updates on in silico binding
of diagnostic assays, 3D protein structure modeling, and
investigation of potential drug targets6. Recently, SARS-CoV-2
mutations have been identified in various regions that could
pose problems to vaccine efficiency or display increased
virulence and transmissibility (European Centre for Disease
Prevention and Control [ECDC], 2020; Koopmans, 2021;
Oude Munnink et al., 2021).
However, sequencing of viral genomes directly from patient
samples is often hindered by the high amount of human
background sequences. To achieve full and deep coverage
of the viral genomes, the labor-, time-, and cost-intensive
generation of many million reads is often necessary. To increase
the number of generated viral reads, preceding culturing
of the viral material on cells can be performed. For the
enrichment of SARS-CoV-2, a hybridization-based approach
with nucleotide baits has been invented, but the method has not
yet been validated and, regarding time, is more extensive than
other approaches, for example amplification-based enrichment
methods (Nasir et al., 2020).
In this study, we report the development of a multiplex-
PCR and MinION sequencing approach (AmpliCoV)
for whole-genome sequencing of SARS-CoV-2. We have
shown that AmpliCoV provides sensitive (up to relative
concentrations of a Ct value of 35 with the Sequencing by
Ligation Kit) whole-genome sequencing of SARS-CoV-2
and sequencing times of only 30 min until almost complete
genome coverage (shown for Ct 24.7). For high and medium
virus concentrations (Ct < 32), library preparation can be
performed with the Rapid Barcoding Kit with only 10 min of
hands-on time. Whole-genome sequencing of SARS-CoV-2
directly from patient material could be shown successfully,
eliminating time-consuming culturing of the material or deep
6https://www.gisaid.org/
sequencing of many millions of reads to achieve appropriate
coverage of the genome.
However, there are some considerations to be made when
using the AmpliCoV whole-genome sequencing approach. First,
sequencing of the sample with the Sequencing by Ligation Kit and
a relatively low virus concentration (Ct 35) required a sequencing
time of 16:08 h until a relatively low coverage (92.2%) of the
genome was achieved. Sequencing times decreased significantly
for samples with higher virus concentration (09:34 min–
05:55 h for average Ct values from 25–30, genome coverage
of 95.3–99.2%). However, as all samples were sequenced in
a realistic setting of routine diagnostics with different sample
qualities, levels of multiplexing, and numbers of active pores,
the sequencing times were not continuously in correlation with
the virus concentration (e.g., sample AC_05 with a Ct of 17.7
and a sequencing time of 40:09 min (genome coverage 95.9%).
Although sequencing with the Rapid approach can be a flexible
alternative to ligation sequencing, sequencing times were longer
compared to the samples prepared with the Sequencing by
Ligation Kit (01:39–02:42 h compared to 31:16–53:15 min).
In direct comparison the coverage of genomes prepared with
the Rapid kit was slightly, but not significantly higher than
for samples prepared with the Sequencing by Ligation Kit.
For both methods, at higher Ct values, drop out of specific
amplicons was noticed, not related to length of amplicons.
However, for reasons of comparison only 50,000 reads were
analyzed. In most cases, analyzing 100,000 reads per sample
was sufficient for almost complete (>98%) genome percentage
coverages. Genome percentage coverage of clinical samples with
low viral load could also be increased by normalizing the libraries
before sequencing (data not shown). For elucidating an event
of virus transmission, the accuracy of genomes obtained by
AmpliCoV sequencing was as with those genomes generated
by Illumina sequencing, allowing the reliable identification of
SNPs. Furthermore, no differences in the reconstructed genomes
were observed after sample preparation of the same sample
with the Ligation Kit and the Rapid Kit. This is crucial, as
the Rapid kit preparation can be prone to mis-assignment
and crossover of barcodes, leading to false positives called
variants. Obtained coverage was also high enough to draw
conclusions about mutations that occurred recently in Denmark,
the United Kingdom, and elsewhere. We could show that
sequencing of the S gene was possible, although sequencing of
a sample with low viral load (Ct 32.2) resulted in low coverage
depth of one amplicon, with successful identification of only 8 of
9 mutations. However, AmpliCoV can be a superior method to
mutation screening with PCR.
A number of amplicon-based sequencing approaches are
currently being applied for SARS-CoV-2 sequencing, foremost
the Artic network protocol (Freed et al., 2020; Gohl et al.,
2020; Hourdel et al., 2020). Although it has been shown for
all approaches that generation of almost complete SARS-CoV-2
genomes is possible with less than 100,000 reads, the sequencing
of complete genomes can be challenging for samples within
the routine diagnostics, where concentration and quality of the
samples can be low. Although not substantially new, here we
have developed an alternative amplicon-based approach which
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was validated on a number of patient samples (n = 36)
that have been sequenced in the frame work of realistic
routine diagnostics of SARS-CoV-2. We were able to generate
almost complete SARS-CoV-2 genomes, although samples were
sequenced with different levels of multiplexing and also on
low quality Flow Cells, given the low number of active pores.
In comparison to the Artic protocol, our approach offers
flexible usage of primer pool composition (e.g., sub-pooling
of primers targeting only the S gene for specific questions),
reduced PCR times (30 s of annealing compared to 5 min) and
reduced hands-on time (compatible with the Rapid Sequencing
Kit). Furthermore, with an increasing number of mutations
in the SARS-CoV-2 genome over time, mismatches between
primer binding sites and primers might hinder amplification
of some amplicons. To reduce this risk, we have designed
the primers in conserved regions (if possible) between SARS-
CoV and SARS-CoV-2, which might be less susceptible to
mutation and are still matching the huge majority of known
sequences according to in silico testing. The amplification of
up to 81.71% of regions of the SARS-CoV genome shows
that primer binding sites with two mismatches to the primer
sequences provide amplification of the correlated amplicon.
With the further progressing mutation of the SARS-CoV-2
genome, additional primers can be included into the primer
panel, if necessary. However, in comparison to mutant-specific
PCR assays, the AmpliCoV approach will in all probability also
identify unexpected mutations that would be missed by specific
PCR assays, usually failing when mismatches occur in relevant
positions of primers or probes.
CONCLUSION
Genome sequencing has been shown to be an irreplaceable tool
for real-time outbreak investigation, including initial pathogen
detection and characterization, transmission chain tracking,
and protein modeling. In particular, the last months have
demonstrated that the identification of specific mutants is
of highest importance. We have established and evaluated
a whole-genome sequencing method for SARS-CoV-2, called
AmpliCoV, which eliminates time-consuming culturing of the
patient material or bait hybridization. Furthermore, personal data
protection can be ensured, as the amount of sequenced host
DNA is minimized markedly. In combination with the affordable
and field-deployable Oxford Nanopore MinION, whole-genome
sequencing can be performed not only by highly equipped
laboratories, but also by laboratories with limited budgets and
in remote areas, making the contribution to investigating the
SARS-CoV-2 outbreak possible.
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